[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100271250":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":7,"locations":12,"responsibleParty":26,"collaborators":7,"id":28,"slug":29,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":33,"acronym":34,"eligibilityCriteria":35,"healthyVolunteers":30,"sex":36,"minAge":7,"maxAge":7,"enrollmentInfo":37,"targetDuration":40,"studyType":41,"phases":7,"briefSummary":42,"conditions":43,"keywords":7,"overallStatus":45,"whyStopped":7,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":54},{"fullName":5,"class":6},"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"Gallium-68 DOTA TATE PET scan","One PET\u002FCT scan using Gallium-68 DOTA TATE",[13],{"facility":14,"status":7,"city":15,"state":16,"zip":17,"country":18,"countryCode":19,"cosmosGeoPoint":20,"geoPoint":25,"contacts":7},"Centre hospitalier universitaire de Sherbrooke","Sherbrooke","Quebec","J1H 5N4","Canada","CA",{"type":21,"coordinates":22},"Point",[23,24],-71.89908,45.40008,{"lat":24,"lon":23},{"type":27,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100271250","study-to-measure-the-safety-of-68ga-dota-tate-petct-in-the-diagnosis-of-tumors-expressing-somatostatin-receptors-100271250",false,"NCT02810600","Study to Measure the Safety of 68Ga-DOTA-TATE PET\u002FCT in the Diagnosis of Tumors Expressing Somatostatin Receptors","Phase II Study to Measure the Safety of 68Ga-DOTA-TATE PET\u002FCT in the Diagnosis of Tumors Expressing Somatostatin Receptors","PET\u002FGa68","Inclusion Criteria:\n\n1. Patients with suspected or proven tumors expressing Somatostatin receptors\n2. Informed consent by patient (or parents if patient is less than 18 years of age)\n\nExclusion Criteria:\n\n1. Pregnancy (confirmed). In the case of a diagnostic procedure in a patient who is or may be pregnant, a clinical decision is necessary considering the benefits against the possible harm of carrying out any procedure.\n2. Patient refusal to participate.\n3. Impossibility to tolerate a decubitus position for 25 minutes\n4. Prior allergic reaction to DOTA-TATE or somatostatin analogs","ALL",{"count":38,"type":39},2120,"ACTUAL","2 Days","OBSERVATIONAL","Phase-II, prospective, open label, no control group to assess the safety of 68Ga-DOTA-TATE injection in patients with suspected or diagnosed with tumors expressing somatostatin receptors. Each included patient will receive an administered dose of 50 mcg or less of the peptide (DOTA-TATE) and a range of activity between 100 - 200 MBq of 68Ga-DOTA-TATE.\n\nThe efficacy of 68Ga-DOTA-TATE in assessing this kind of tumors has been proved by numerous studies.",[44],"Neuroendocrine Tumors","COMPLETED","2021-05-17",{"date":48,"type":39},"2021-05-18",{"date":50,"type":39},"2016-06-08",{"date":52,"type":39},"2020-05-29",{"name":5,"class":6},1]